CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
April 09 2024 - 7:00AM
Business Wire
Late-Breaking Abstract Presentation to Showcase
Results from SHORE Registry Highlighting Benefits of Surveillance
with HeartCare
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ – a leading
precision medicine company focused on the discovery, development,
and commercialization of clinically differentiated, high-value
healthcare solutions for transplant patients and caregivers – today
announced that CareDx and study collaborators will be presenting
the latest data featuring CareDx’s cardiothoracic portfolio at the
International Society for Heart and Lung Transplantation (ISHLT)
44th Annual Meeting & Scientific Sessions, taking place from
April 10-13 in Prague, Czech Republic.
CareDx, along with study collaborators from leading transplant
centers, will present cutting-edge developments that underscore the
clinical significance of CareDx’s cardiothoracic portfolio. This
includes AlloSure Heart, AlloMap Heart, HeartCare, AlloSure Lung,
and AiCAV (in development); featured in over 25 oral presentations,
posters, and two symposia. These presentations will highlight
real-world applications driving advancements in heart and lung
transplantation.
“We are proud to have a leading presence once again at this
pivotal heart and lung transplant meeting. We are especially
pleased to share new results from our SHORE registry validating the
clinical utility of surveillance using HeartCare testing,” said
Alex Johnson, President of Patient and Testing Services, and member
of the Office of the CEO.
A leading group of experts in the field will present on the use
of HeartCare™, AlloSure® Heart, AlloMap® Heart, and AlloSure Lung
in clinical decision-making and in the management of challenging
real-world scenarios in two CareDx sponsored symposia:
- Heart and Seek: A Case-Based Practical Guide to Multimodal
Molecular Surveillance. Moderated by Yas Moyadei, MD, University
Health Network, Toronto. Panelists include Shelley Hall, MD, Baylor
Scott & White, Farhana Latif MD, Columbia University, and
Jeffrey Teuteberg, MD, Stanford University.
- Innovations in Post-Lung Transplant Care: Integrating Molecular
Diagnostics and Multimodal Remote Monitoring for Enhanced Clinical
Decision-Making. Moderated by Daniel Dilling, MD, Loyola
University. Panelists include Alice Gray, MD, University of
Colorado, and Jake G. Natalini, MD, NYU Langone.
“We look forward to sharing the latest findings from the SHORE
registry, revealing new insights that can be obtained by
integrating AlloMap gene-expression profiling and AlloSure
donor-derived cell-free DNA in assessing allograft health after
heart transplantation. Through this molecular monitoring approach,
we’re not just identifying early signs of rejection, we’re ushering
in a new era of proactive care because we can anticipate long-term
outcomes after heart transplantation more precisely than ever
before,” said Kiran Khush, MD, MAS, Cardiologist, Professor of
Cardiovascular Medicine, Stanford Medicine.
“I look forward to moderating the scientific discussion at the
lung transplant symposium. The introduction of diagnostics like
AlloSure Lung represents a unique opportunity to address the
longstanding challenges in post-lung transplant care, characterized
by historically suboptimal long-term outcomes. Integrating
molecular diagnostics with AlloHome remote monitoring holds
significant potential to propel us forward in clinical
decision-making and, most importantly, to improve patient
outcomes,” said Daniel Dilling, MD, Professor of Medicine, Loyola
University Chicago Stritch School of Medicine, Medical Director,
Lung and Heart-Lung Transplant Programs Loyola University.
For a complete listing of abstracts, oral presentations and
posters please follow this link.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
benefits and results that may be achieved with AlloSure Heart,
AlloMap Heart, HeartCare, AlloSure Lung, AiCAV, and other CareDx
products, and statements regarding the interim study results of
CareDx’s SHORE registry at the 2024 International Society for Heart
and Lung Transplantation Meeting (the “ISHLT Presentation”). These
forward-looking statements are based upon information that is
currently available to CareDx and its current expectations, speak
only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including risks that CareDx does not realize
the expected benefits of AlloSure Heart, AlloMap Heart, HeartCare,
AlloSure Lung, AiCAV, or other CareDx products or its ISHLT
Presentation; risks that the ISHLT Presentation and the data to be
presented may not follow the agenda as stated in this press
release; risks that the findings in the studies supporting the data
may be inaccurate, general economic and market factors; and other
risks discussed in CareDx’s filings with the SEC, including the
Annual Report on Form 10-K for the fiscal year ended December 31,
2023 filed by CareDx with the SEC on February 28, 2024 and other
reports that CareDx has filed with the SEC. Any of these may cause
CareDx’s actual results, performance, or achievements to differ
materially and adversely from those anticipated or implied by
CareDx’s forward-looking statements. CareDx expressly disclaims any
obligation, except as required by law, or undertaking to update or
revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409004434/en/
CareDx, Inc. Media Relations Anna Czene 818-731-2203
aczene@caredx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024